시장보고서
상품코드
1949815

베타 차단약 시장 보고서(2026년)

Beta Blockers Global Market Report 2026

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

베타 차단약 시장 규모는 최근 현저한 성장을 달성하고 있습니다. 2025년 102억 2,000만 달러에서 2026년에는 108억 2,000만 달러로, CAGR 5.8%로 확대가 전망됩니다. 지난 수년간의 성장 요인으로는 심혈관 질환 유병률 증가, 제네릭 베타 차단제 도입, 헬스케어 인프라 확충, 의사들의 인식 개선, 도시화, 라이프스타일의 변화 등을 들 수 있습니다.

향후 수년간 베타 차단약 시장 규모는 견고한 성장이 전망됩니다. 2030년에는 139억 6,000만 달러에 달하며, CAGR은 6.6%에 달할 전망입니다. 예측 기간 중의 성장 요인으로는 정밀의료의 발전, 디지털 헬스와의 통합, 신흥 시장 확대, 새로운 약물전달 기술, 개인 맞춤형 치료 접근법 등을 꼽을 수 있습니다. 예측 기간 중 주요 동향으로는 심혈관 질환에 대한 베타 차단제 채택 증가, 예방 의료에서 심장 의료에 대한 인식 증가, 병원 및 소매 약국 네트워크 확대, 새로운 베타 차단제 제제 개발, 고혈압 및 심장 질환을 앓고 있는 고령 인구 증가 등을 들 수 있습니다.

향후 수년간 심혈관 질환의 발생률 증가가 베타 차단제 시장 확대를 견인할 것으로 예측됩니다. 심혈관 질환은 심장과 혈관에 영향을 미치는 광범위한 질환군을 말합니다. 심혈관 질환 증가는 주로 건강에 해로운 식습관, 좌식 생활, 불충분한 신체 활동, 담배 소비, 비만율 증가에 기인합니다. 베타 차단제는 심장 및 혈관계에 여러 가지 유익한 효과를 발휘하여 심혈관 질환을 감소시키는 데 기여합니다. 그 결과, 심혈관 질환 사례 증가가 베타 차단제 시장 성장에 크게 기여하고 있습니다. 예를 들어 미국 비영리단체인 미국심장협회(American Heart Association)에 따르면 2024년 1월 기준 심혈관 질환으로 인한 연령 조정 사망률은 2024년 10만 명당 233.3명으로 2023년 10만 명당 224.4명에서 4.0% 상승할 것으로 예상했습니다. 증가를 보였습니다. 따라서 심혈관 질환 발생률 증가는 베타 차단제 시장의 성장을 가속하고 있습니다.

베타 차단제 시장에서 사업을 운영하고 있는 주요 기업은 중증 고혈압 관리와 효과적인 혈압 강하를 실현하는 첨단 베타 차단제 도입에 집중하며 경쟁 우위를 강화하기 위해 노력하고 있습니다. 베타 차단제는 말초 세동맥의 알파 아드레날린 수용체를 차단하여 말초 저항을 감소시켜 중증 고혈압 치료와 혈압 강하에 중요한 역할을 합니다. 동시에 베타차단 작용으로 반사성 교감신경 자극으로부터 심장을 보호합니다. 예를 들어 2023년 3월 영국에 본사를 둔 제약회사 히쿠마 파마슈티컬스(Hikuma Pharmaceuticals)는 중증 고혈압 치료 및 혈압 관리를 목적으로 프리필드 시린지 형태의 라베타롤 염산염 주사제(USP)를 미국에서 출시했습니다. 라베탈롤은 단일 제제에서 선택적 경쟁적 α1 아드레날린 수용체 차단 작용과 비선택적 경쟁적 베타 아드레날린 수용체 차단 작용을 동시에 가지고 있습니다. 주로 말초 세동맥의 알파 아드레날린 수용체를 차단하여 말초 저항을 감소시켜 혈압을 떨어뜨립니다. 라베탈롤은 비선택적 베타 아드레날린 수용체 길항제로 분류되며, 전신의 베타1 수용체와 베타2 수용체를 모두 억제합니다.

자주 묻는 질문

  • 베타 차단약 시장 규모는 어떻게 변화하고 있나요?
  • 베타 차단약 시장의 성장 요인은 무엇인가요?
  • 향후 베타 차단약 시장의 주요 동향은 무엇인가요?
  • 심혈관 질환의 발생률 증가가 베타 차단제 시장에 미치는 영향은 무엇인가요?
  • 베타 차단제 시장에서 활동하는 주요 기업은 어디인가요?

목차

제1장 개요

제2장 시장의 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 용도 산업의 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의에 의한 공급망에 대한 영향, Covid가 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 시장의 세계 TAM(Total Addressable Market)

제9장 시장 세분화

제10장 지역별·국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 대기업과 혁신적 기업

제38장 세계의 시장 경쟁 벤치마킹과 대시보드

제39장 주요 합병과 인수

제40장 시장의 잠재력이 높은 국가, 부문, 전략

제41장 부록

KSA 26.03.26

Beta blockers, also referred to as beta-adrenergic blocking agents, are a group of medications widely used to manage various cardiovascular disorders by reducing heart activity. They are commonly prescribed for controlling blood pressure, treating angina, managing heart failure, and addressing certain cardiac rhythm abnormalities.

The main categories of beta blockers include non-selective agents and selective agents. Non-selective agents in the beta-blockers market are medications that block beta-adrenergic receptors without targeting a specific receptor subtype. These agents help regulate several physiological functions, such as heart rate, blood pressure, bronchial smooth muscle tone, and peripheral vascular resistance. The indications for beta blocker use include angina pectoris, heart failure, hypertension, and other conditions, which can be treated using drugs such as betaxolol, acebutolol, esmolol, and others. Beta blockers are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are used in the treatment of cardiac diseases, hypertension, glaucoma, and other conditions.

Tariffs have influenced the beta blockers market by increasing import costs for raw materials and finished pharmaceutical products, particularly impacting hospital and retail pharmacy segments in regions such as Europe, North America, and Asia-Pacific. This has led to higher production costs and potential supply delays, while encouraging manufacturers to explore local sourcing, optimize production, and invest in cost-efficient drug formulations. Certain domestic manufacturers may benefit from reduced competition due to tariff barriers.

The beta blockers market research report is one of a series of new reports from The Business Research Company that provides beta blockers market statistics, including beta blockers industry global market size, regional shares, competitors with a beta blockers market share, detailed beta blockers market segments, market trends and opportunities, and any further data you may need to thrive in the beta blockers industry. This beta blockers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The beta blockers market size has grown strongly in recent years. It will grow from $10.22 billion in 2025 to $10.82 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to rising prevalence of cardiovascular diseases, introduction of generic beta blockers, growing healthcare infrastructure, increasing physician awareness, urbanization and lifestyle changes.

The beta blockers market size is expected to see strong growth in the next few years. It will grow to $13.96 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to advancements in precision medicine, digital health integration, emerging markets expansion, novel drug delivery technologies, personalized treatment approaches. Major trends in the forecast period include increasing adoption of beta blockers for cardiovascular diseases, growing awareness of preventive cardiac healthcare, expansion of hospital and retail pharmacy networks, development of novel beta blocker formulations, rising geriatric population with hypertension and heart disorders.

The increasing incidence of cardiovascular diseases is anticipated to drive the expansion of the beta blockers market in the coming years. Cardiovascular diseases are a broad category of conditions that affect the heart and blood vessels. The rising occurrence of cardiovascular diseases is largely attributed to unhealthy dietary habits, sedentary lifestyles, inadequate physical activity, tobacco consumption, and growing obesity rates. Beta blockers help reduce cardiovascular events by exerting multiple beneficial effects on the heart and vascular system. As a result, the growing number of cardiovascular disease cases is contributing significantly to the growth of the beta blockers market. For example, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted mortality rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, representing a 4.0% rise from 224.4 per 100,000 in 2023. Therefore, the rising incidence of cardiovascular diseases is fueling the growth of the beta blockers market.

Leading companies operating in the beta blockers market are concentrating on the introduction of advanced beta-blocking agents for the management of severe hypertension and effective blood pressure reduction to strengthen their competitive position. Beta blockers play an important role in treating severe hypertension and lowering blood pressure by blocking peripheral arteriolar alpha-adrenoceptors, which reduces peripheral resistance, while simultaneous beta-blockade protects the heart from reflex sympathetic stimulation. For instance, in March 2023, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, launched Labetalol Hydrochloride Injection, USP, in a prefilled syringe format in the United States for the treatment of severe hypertension and blood pressure control. Labetalol combines selective, competitive alpha1-adrenergic blocking activity with nonselective, competitive beta-adrenergic blocking effects in a single formulation. It primarily works by blocking peripheral arteriolar alpha-adrenoceptors, thereby lowering peripheral resistance and reducing blood pressure. Labetalol is classified as a non-selective beta-adrenergic receptor antagonist, meaning it inhibits both beta-1 and beta-2 receptors throughout the body.

In April 2023, Marksans Pharma, an India-based pharmaceutical company, acquired a manufacturing facility from Teva Pharmaceutical Industries for an undisclosed amount. Through this acquisition, Marksans Pharma aims to significantly increase its production capacity in India, strengthen its position as a cost-efficient manufacturer, and effectively meet the rising demand from its customers. Teva Pharmaceutical Industries Ltd. is an Israel-based multinational pharmaceutical company involved in the development, manufacturing, and commercialization of generic and specialty pharmaceutical products.

Major companies operating in the beta blockers market are Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca plc, Johnson and Johnson, Eli Lilly and Company, Sanofi SA, Bristol-Myers Squibb Company, Bayer AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Abbott Laboratories, Eagle Pharmaceuticals Inc., Neon Healthcare Ltd., Midas Pharma GmbH, AbbVie Inc., Mylan N.V., Boehringer Ingelheim International GmbH, Aspen Pharmacare Holdings Limited, Lupin Limited, Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Sandoz International GmbH, Wockhardt Ltd., Endo Pharmaceuticals Inc., Apotex Inc.

North America was the largest region in the beta blockers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global beta-blockers market report during the forecast period. The regions covered in the beta blockers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the beta blockers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The beta blockers market consists of sales of sales of metoprolol, nebivolol, timolol, and labetalol. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Beta Blockers Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses beta blockers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for beta blockers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The beta blockers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Type: Non-selective Agents; Selective Agents
  • 2) By Indication: Angina Pectoris; Heart Failure; High Blood Pressure; Other Indications
  • 3) By Drugs: Betaxolol; Acebutolol; Esmolol; Other Drugs
  • 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
  • 5) By Application: Cardiac Diseases; Hypertension; Glaucoma; Other Applications
  • Subsegments:
  • 1) By Non-Selective Agents: Propranolol; Nadolol; Timolol
  • 2) By Selective Agents: Atenolol; Metoprolol; Bisoprolol; Nebivolol
  • Companies Mentioned: Pfizer Inc.; Novartis AG; Merck & Co. Inc.; AstraZeneca plc; Johnson and Johnson; Eli Lilly and Company; Sanofi SA; Bristol-Myers Squibb Company; Bayer AG; GlaxoSmithKline plc; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Amneal Pharmaceuticals LLC; Abbott Laboratories; Eagle Pharmaceuticals Inc.; Neon Healthcare Ltd.; Midas Pharma GmbH; AbbVie Inc.; Mylan N.V.; Boehringer Ingelheim International GmbH; Aspen Pharmacare Holdings Limited; Lupin Limited; Torrent Pharmaceuticals Ltd.; Dr. Reddy's Laboratories Ltd.; Cipla Ltd.; Sandoz International GmbH; Wockhardt Ltd.; Endo Pharmaceuticals Inc.; Apotex Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Beta Blockers Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Beta Blockers Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Beta Blockers Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Beta Blockers Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.3 Industry 4.0 & Intelligent Manufacturing
    • 4.1.4 Artificial Intelligence & Autonomous Intelligence
    • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.2. Major Trends
    • 4.2.1 Increasing Adoption Of Beta Blockers For Cardiovascular Diseases
    • 4.2.2 Growing Awareness Of Preventive Cardiac Healthcare
    • 4.2.3 Expansion Of Hospital And Retail Pharmacy Networks
    • 4.2.4 Development Of Novel Beta Blocker Formulations
    • 4.2.5 Rising Geriatric Population With Hypertension And Heart Disorders

5. Beta Blockers Market Analysis Of End Use Industries

  • 5.1 Hospitals
  • 5.2 Cardiology Clinics
  • 5.3 Retail Pharmacies
  • 5.4 Online Pharmacies
  • 5.5 Research & Diagnostic Centers

6. Beta Blockers Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Beta Blockers Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Beta Blockers PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Beta Blockers Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Beta Blockers Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Beta Blockers Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Beta Blockers Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Beta Blockers Market Segmentation

  • 9.1. Global Beta Blockers Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Non-selective Agents, Selective Agents
  • 9.2. Global Beta Blockers Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Angina Pectoris, Heart Failure, High Blood Pressure, Other Indications
  • 9.3. Global Beta Blockers Market, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Betaxolol, Acebutolol, Esmolol, Other Drugs
  • 9.4. Global Beta Blockers Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
  • 9.5. Global Beta Blockers Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Cardiac Diseases, Hypertension, Glaucoma, Other Applications
  • 9.6. Global Beta Blockers Market, Sub-Segmentation Of Non-Selective Agents, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Propranolol, Nadolol, Timolol
  • 9.7. Global Beta Blockers Market, Sub-Segmentation Of Selective Agents, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Atenolol, Metoprolol, Bisoprolol, Nebivolol

10. Beta Blockers Market Regional And Country Analysis

  • 10.1. Global Beta Blockers Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Beta Blockers Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Beta Blockers Market

  • 11.1. Asia-Pacific Beta Blockers Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Beta Blockers Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Beta Blockers Market

  • 12.1. China Beta Blockers Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Beta Blockers Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Beta Blockers Market

  • 13.1. India Beta Blockers Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Beta Blockers Market

  • 14.1. Japan Beta Blockers Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Beta Blockers Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Beta Blockers Market

  • 15.1. Australia Beta Blockers Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Beta Blockers Market

  • 16.1. Indonesia Beta Blockers Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Beta Blockers Market

  • 17.1. South Korea Beta Blockers Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Beta Blockers Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Beta Blockers Market

  • 18.1. Taiwan Beta Blockers Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Beta Blockers Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Beta Blockers Market

  • 19.1. South East Asia Beta Blockers Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Beta Blockers Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Beta Blockers Market

  • 20.1. Western Europe Beta Blockers Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Beta Blockers Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Beta Blockers Market

  • 21.1. UK Beta Blockers Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Beta Blockers Market

  • 22.1. Germany Beta Blockers Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Beta Blockers Market

  • 23.1. France Beta Blockers Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Beta Blockers Market

  • 24.1. Italy Beta Blockers Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Beta Blockers Market

  • 25.1. Spain Beta Blockers Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Beta Blockers Market

  • 26.1. Eastern Europe Beta Blockers Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Beta Blockers Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Beta Blockers Market

  • 27.1. Russia Beta Blockers Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Beta Blockers Market

  • 28.1. North America Beta Blockers Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Beta Blockers Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Beta Blockers Market

  • 29.1. USA Beta Blockers Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Beta Blockers Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Beta Blockers Market

  • 30.1. Canada Beta Blockers Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Beta Blockers Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Beta Blockers Market

  • 31.1. South America Beta Blockers Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Beta Blockers Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Beta Blockers Market

  • 32.1. Brazil Beta Blockers Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Beta Blockers Market

  • 33.1. Middle East Beta Blockers Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Beta Blockers Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Beta Blockers Market

  • 34.1. Africa Beta Blockers Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Beta Blockers Market, Segmentation By Type, Segmentation By Indication, Segmentation By Drugs, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Beta Blockers Market Regulatory and Investment Landscape

36. Beta Blockers Market Competitive Landscape And Company Profiles

  • 36.1. Beta Blockers Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Beta Blockers Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Beta Blockers Market Company Profiles
    • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis

37. Beta Blockers Market Other Major And Innovative Companies

  • Eli Lilly and Company, Sanofi SA, Bristol-Myers Squibb Company, Bayer AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Abbott Laboratories, Eagle Pharmaceuticals Inc., Neon Healthcare Ltd., Midas Pharma GmbH, AbbVie Inc., Mylan N.V., Boehringer Ingelheim International GmbH

38. Global Beta Blockers Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Beta Blockers Market

40. Beta Blockers Market High Potential Countries, Segments and Strategies

  • 40.1 Beta Blockers Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Beta Blockers Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Beta Blockers Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제